- Citations, last 5 years
- 51
- Works, last 5 years
- 28
- h-index
- 39
- Scientists listed
- 3
- Grants since 2016
- 11
Grants received
2024–2025 · contract · N01
TASK ORDER 7 - DOK7
Akiva Kosowsky · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2023–2024 · contract · N01
TO6 - GENERATING MONOCLONAL CELL LINES, MONOCLONAL ANTIBODIES, AND LABELED MONOCLONAL ANTIBODIES AGAINST HUMAN AND MOUSE COLQ
Akiva Kosowsky · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2023–2024 · contract · N01
TO6 - GENERATING MONOCLONAL CELL LINES, MONOCLONAL ANTIBODIES, AND LABELED MONOCLONAL ANTIBODIES AGAINST HUMAN AND MOUSE COLQ
Akiva Kosowsky · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
Ginette Serrero · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2018–2023 · research · R44
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
Ginette Serrero · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2018–2026 · research · R44
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
Ginette Serrero · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2017–2025 · research · R44
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
Ginette Serrero · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2017–2018 · research · R43
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
Ginette Serrero · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2017–2023 · research · R44
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
Ginette Serrero · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2017–2023 · research · R44
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
Ginette Serrero · A&G Pharmaceutical (United States) · funded by National Institutes of Health
2012–2023 · research · R44
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
Ginette Serrero · A&G Pharmaceutical (United States) · funded by National Institutes of Health
